Pollinex^® Quattro: a novel and well–tolerated, ultra short–course allergy vaccine

References

• Gell PGH, Coombs RRA (Eds). The classification of allergic reactions underlying disease. In: Clinical Aspects of Immunology. Blackwell Science, London, UK 317–320 (1963).
   Google Scholar
• Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. Med. Clin. N. Am.90(1), 17–38 (2006).
   PubMed Web of Science ®Google Scholar
• Johnstone DE, Dutton A, Dutton AM. The value of hyposensitization therapy for bronchial asthma in children – a 14-year study. Pediatrics42(5), 793–802 (1968).
   PubMed Web of Science ®Google Scholar
• Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol.109(2), 251–256 (2002).
   PubMed Web of Science ®Google Scholar
• Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy61(2), 198–201 (2006).
   PubMed Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene, and household size. Br. Med. J.299(6710), 1259–1260 (1989).
   PubMed Web of Science ®Google Scholar
• Nygaard UC, Aase A, Lovik M. The allergy adjuvant effect of particles – genetic factors influence antibody and cytokine responses. BMC Immunol.6, 11 (2005).
   PubMed Web of Science ®Google Scholar
• Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies. Clin. Ther.22(3), 342–350 (2000).
   PubMed Web of Science ®Google Scholar
• Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. (4), CD001186 (2003).
   Google Scholar
• Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J. Clin. Invest.114(10), 1389–1397, (2004).
   PubMed Web of Science ®Google Scholar
• Schmidt-Weber CB, Blaser K. Immunological mechanisms of specific allergen immunotherapy. Inflamm. Allergy Drug Targets5(1), 15–21 (2006).
   PubMedGoogle Scholar
• Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N. Engl. J. Med.353(18), 1934–1944 (2005).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol.81(5 Pt 1), 401–405 (1998).
   PubMed Web of Science ®Google Scholar
• Li J, Lockey RF, Bernstein L, Portnoy JM, Nicklas RA. Allergen immunotherapy: a practice parameter. Ann. Allergy Asthma Immunol.90(Suppl. 1), 1–40 (2003).
   Web of Science ®Google Scholar
• Theodoropoulos DS, Lockey RF. Allergen immunotherapy: guidelines, update, and recommendations of the World Health Organization. Allergy Asthma Proc.21(3), 159–166 (2000).
   PubMed Web of Science ®Google Scholar
• Wheeler AW, Woroniecki SR. Modern approaches to therapeutic vaccination as treatment for type 1 respiratory hypersensitivity (allergy) treatment. Expert Rev. Vaccines5(1), 27–31 (2006).
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med.341(7), 468–475 (1999).
   PubMed Web of Science ®Google Scholar
• Maasch HJ, Marsh DG. Standardized extracts modified allergens – allergoids. Clin. Rev. Allergy5(1), 89–106 (1987).
   PubMedGoogle Scholar
• Wheeler AW, Jenkins PM, Moran DM. Chemical modification of crude timothy grass pollen extract. II. Class and specificity of antibodies induced by chemically modified timothy grass pollen extract. Int. Arch. Allergy Appl. Immunol.50(6), 709–728 (1976).
   PubMedGoogle Scholar
• Overell BG. Modified allergens: criteria for standardisation. Arb. Paul Ehrlich Inst. Bundesamt Sera Impfstoffe Frankf A. M. (82), 233–241 (1988).
   PubMedGoogle Scholar
• Baldrick P, Richardson D, Wheeler AW. Review of L-tyrosine confirming its safe human use as an adjuvant. J. Appl. Toxicol.22(5), 333–344 (2002).
   PubMed Web of Science ®Google Scholar
• Baldrick P, Richardson D, Elliott G, Wheeler AW. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul. Toxicol. Pharmacol.35(3), 398–413 (2002).
   PubMed Web of Science ®Google Scholar
• Persing DH, Coler RN, Lacy MJ et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol.10(10 Suppl.), S32–S37 (2002).
   PubMed Web of Science ®Google Scholar
• Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy33(9), 1198–1208 (2003).
   PubMed Web of Science ®Google Scholar
• Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy60(5), 678–684 (2005).
   PubMed Web of Science ®Google Scholar
• Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol.126(2), 135–139 (2001).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy56(6), 498–505 (2001).
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid A. Allergologie25, 466–474 (2002).
   Google Scholar
• Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. (Madr.)31(5), 270–277 (2003).
   PubMedGoogle Scholar
• Stuck BA, Schneider-Gene S, Schafer D, Klimek L, Hormann K. Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL). Allergy Clin. Immunol. Int. J. World Allergy Org.16(2), 60–64 (2004).
   Google Scholar
• Rover AC, Reimann S, Zuberbier T, Worm M. Immunophenotypic characterization of peripheral B cells. During short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J. Investig. Allergol. Clin. Immunol.12(4), 227–234 (2002).
   PubMed Web of Science ®Google Scholar
• von Baehr V, Hermes A, von Baehr R et al. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J. Investig. Allergol. Clin. Immunol.15(4), 234–241 (2005).
   PubMed Web of Science ®Google Scholar
• Patel P, Salapatek AM, Shah C et al. Assessment of the residual allergenicity of Pollinex Quattro Ragweed using skin prick testing. Ann. Allergy Asthma Immunol. (2006).
   Google Scholar
• Moran DM, Wheeler AW. Chemical modification of crude timothy grass pollen extract. I. Antigenicity and immunogenicity changes following amino group modification. Int. Arch. Allergy Appl. Immunol.50(6), 693–708 (1976).
   PubMedGoogle Scholar
• Patel P, Salapatek AM, Shah C et al. Evaluation of the safety and imunogenicity of Pollinex Quattro Grass in patients suffering from grass and rye allergies. Ann. Allergy Asthma Immunol. (2006).
   Google Scholar
• Patel P, Salapatek AM, Shah C et al. The safety and clinical efficacy of Pollinex Quattro Ragweed assessed in an environmental exposure chamber. Ann. Allergy Asthma Immunol. (2006).
   Google Scholar
• Sauve H, Patel P, Talwar N. Development plan for an environmental exposure chamber (EEC) rhinoconjunctivitis quality of life questionaire (RQLQ) in the EEC Setting. XXV Congress of the European Academy of Allergology and Clinical Immunology (EAACI) (2006).
   Google Scholar
• Drachenberg KJ, Proell S, Urban E, Woroniecki SR. Short-term immunotherpay using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int. Rev. Allergol. Clin. Immunol.8(4), 219–223 (2002).
   Google Scholar
• Clay M, Urban E. Specific immunotherapy using pollen allergoids adjuvanted with monophosphory lipid A over a three year period shows good efficacy and increased tolerability. Clin. Exp. Allergy35(10), 1411 (2005).
   Google Scholar
• Commision Directive 2005/61/EC: implementing directive of the European Parliament and of the Council as regards to traceability requirements and notification of serious adverse reactions and events. In: L 256/32, 30 September (2005).
   Google Scholar
• Hopkins M, Lees BG, Richardson DG, Woroniecki SR, Wheeler AW. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL). Allergol. Immunopathol. (Madr)29(6), 245–254 (2001).
   PubMedGoogle Scholar
• Newland B, Lees BG, Woroniecki SR. Standardisation of a glutaraldehyde-modified allergen tyrosine adsorbed vaccine using an assay system with a europium label. Intl. Rev. Allergol. Clin. Immunol.7(3), 95–101 (2001).
   Google Scholar
• Baldrick P, Richardson D, Wheeler AW, Woroniecki SR. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy. J. Appl. Toxicol.24(4), 261–268 (2004).
   PubMed Web of Science ®Google Scholar
• Mahler V, Vrtala S, Kuss O et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy34(1), 115–122 (2004).
   PubMed Web of Science ®Google Scholar
• Evans JT, Cluff CW, Johnson DA et al. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines2(2), 219–229 (2003).
   PubMedGoogle Scholar
• Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol. Immunopathol. (Madr.)33(6), 296–302 (2005).
   PubMedGoogle Scholar